A U.S. District Judge on Wednesday ruled against Amgen Inc. in a patent dispute between the Thousand Oaks biotech company and rival Sanofi, based in Paris. According to a Reuters report, the judge set aside a jury verdict that Amgen’s patents were valid. In the lawsuit, Amgen sought to stop Sanofi and New York’s Regeneron Pharmaceuticals Inc. from selling Praulent, a cholesterol medication. The drug is in direct competition with Amgen’s Repatha, which also treats cholesterol. Andrews ruled that Amgen’s patent claims were invalid because they didn’t provide sufficient information regarding the drug’s innovations. “Today, the United States District Court in Delaware granted a motion in part reversing the jury verdict from February which had upheld the validity of Amgen’s patents. The Court denied the motions on written description and for a new trial,” Amgen said in a statement. “We disagree with the court’s decision in reversing the jury verdict on enablement and will seek review by the appellate court.” The long-running lawsuit has been in the courts since 2014. Shares of Amgen (AMGN) closed Wednesday up $1.03, or half of one percent, to $207.52 on the Nasdaq.